Biodesix (BDSX) vs Exagen (XGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Biodesix (BDSX) has outperformed Exagen (XGN) over the past year, gaining 261.9% versus a loss of 24.3%. Over five years, XGN leads with a -34.3% price change compared with -82.4% for BDSX. Biodesix is the larger company by market cap ($270.5 million vs $196.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDSX | XGN |
|---|---|---|
| Share price | $25.64 | $8.12 |
| Market cap | $270.53M | $196.59M |
| 1-day change | -2.95% | -2.23% |
| YTD return | +288.53% | +36.51% |
| 1-year return | +261.92% | -24.27% |
| 5-year return | -82.39% | -34.28% |
| EPS (TTM) | $-3.10 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.97 | $12.23 |
| 52-week low | $5.26 | $2.59 |
| Distance from 52-week high | -19.80% | -33.65% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +45.59% | +24.95% |
| Average volume | 100.74K | 328.42K |
| Shares outstanding | 10.55M | 24.23M |
| Employees | 334 | 216 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BDSX has outperformed XGN by 286.2 percentage points over the past year.
About Biodesix
BDSX stock →Biodesix, Inc. operates as a diagnostic solutions company.
Health Care · Medical Specialities · 334 employees
About Exagen
XGN stock →Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
Health Care · Medical Specialities · 216 employees
BDSX vs XGN FAQ
Which is bigger, Biodesix or Exagen?
Biodesix (BDSX) is larger, with a market capitalization of $270.53M compared with $196.59M for Exagen (XGN).
Which stock has performed better over the past year, BDSX or XGN?
BDSX returned +261.92% over the past 12 months, compared with -24.27% for XGN (price return, excluding dividends). Past performance does not predict future results.
Are Biodesix and Exagen in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.